The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
John Howard Sampson
No relevant relationships to disclose
Gordana Vlahovic
No relevant relationships to disclose
Annick Desjardins
No relevant relationships to disclose
Henry S. Friedman
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Joachim M. Baehring
No relevant relationships to disclose
David Hafler
No relevant relationships to disclose
Linda Rollin
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Vlad Coric
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Susan N. Perez
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
David A. Reardon
Consultant or Advisory Role - Amgen; Genentech; Momenta Pharmaceuticals; Novartis; Roche; Stemline Therapeutics
Honoraria - Amgen; Momenta Pharmaceuticals; Novartis; Roche; Stemline Therapeutics